Project Grant HT94252310577

This federal Project Grant award for $1,493,271 was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2024. The award will support a 3-year research project led by The Washington University to conduct "Precision Brain Mapping and Deep Phenotyping in Pediatric Brain Tumor Patients." The key objectives of the research are to: 1) Determine the relationship between long-term cognitive outcomes and functional brain...

This $1,336,000 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program supports the development of a rapid, motion-robust, and low-gadolinium MRI technology for pediatric brain tumors. The key objectives are to (1) develop cutting-edge technologies for rapid, motion-robust, and quantitative MRI scans to reduce sedation needs...

This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...

Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $456,414 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2025, through April 30, 2030. This award supports the clinical development and evaluation of B7-H3 Chimeric Antigen Receptor (CAR) T cell therapy for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), a fatal...

Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded a $368,156 Project Grant to the University of California, Los Angeles (UCLA) for a two-year research initiative (June 1, 2026 – May 31, 2028). The award funds research investigating radiation-induced cognitive impairment in cancer patients undergoing cranial radiotherapy. UCLA will conduct mechanistic studies using human induced pluripotent stem cell...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $414,402 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2028. This research project develops multi-modality imaging and biomarker integration methods to improve glioblastoma radiation therapy targeting. The deliverables include: (1) white matter infiltrative risk maps derived from diffusion...

This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...

Summary Children's Mercy Hospital received a $1.51 million Project Grant from the National Center for Complementary and Integrative Health under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), awarded on September 22, 2025, with completion targeted for August 31, 2028. The grant funds a feasibility trial evaluating Immersive Neurofeedback Self-Regulation Training (INSERT), a home-based mind-body intervention combining wearable electroencephalogram (EEG)...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...

The University of Texas MD Anderson Cancer Center received a $460,940 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2025, through May 31, 2027. This award supports investigator-initiated research examining how glioma-associated germline risk alleles (single nucleotide polymorphisms or SNPs) impact neurodevelopmental...